The Competing Interests section is incorrect. The Competing Interests section should read: Joshua Field, M.D., M.S., Joel Linden, Ph.D. and David Nathan, M.D. each have consulting agreements with NKT Therapeutics, Inc. Joel Linden, Ph.D. is an inventor on a patent issued to the University of Virginia, which claims the use of adenosine A2A agonists for the treatment of sickle cell disease; he owns shares in Adenosine Therapeutics LLC, which licensed this patent. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.
Reference
Citation: The PLOS ONE Staff (2015) Correction: NF-κB Is Activated in CD4+ iNKT Cells by Sickle Cell Disease and Mediates Rapid Induction of Adenosine A2A Receptors. PLoS ONE 10(2): e0117760. https://doi.org/10.1371/journal.pone.0117760
Published: February 6, 2015
Copyright: © 2015 The PLOS ONE Staff. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited